Guardant Health, Inc.
Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.
Hidalgo Medina Manuel sold 1,700 shares of Guardant Health, Inc. (GH) at an average of $164.24 ($163.94–$164.61, $0.28M total) across 2 trades on 2026-08-05.
CLARK IAN T sold 14,180 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $158.92 ($158.80–$158.98, $2.25M total) across 2 trades on 2026-08-04.
Over the past 7 days, alphai's AI scored 4 news stories mentioning GH (Guardant Health, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent GH coverage spans earnings, insider activity and financial news.
In the last 30 days, GH insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($2.6M). The most active reporter was Hidalgo Medina Manuel with 2 filings. 20% of activity was filed under pre-arranged Rule 10b5-1 plans.
Raised guidance and detailed Shield cost-per-test targets and reimbursement progress, supporting a constructive near-term earnings and margin narrative.
This is a routine insider sale under a director’s direct holdings, with no 10b5-1 plan cited, but it is unlikely to be a standalone fundamental catalyst.
A director open-market sale is typically a low-signal event for fundamentals, but it can add short-term sentiment noise.
The comparison frames competitive positioning for Guardant’s Shield, potentially affecting investor expectations around relative clinical performance and market share.
Analyst target and outlook upgrade reinforce near-term positive sentiment around Guardant’s liquid biopsy growth and MRD pipeline catalysts.
alphai scores every news story that mentions GH with an AI model for sentiment and relevance, and aggregates insider trades from Guardant Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.
7 min readHidalgo Medina Manuel sold 1,700 shares of Guardant Health, Inc. (GH) at an average of $164.24 ($163.94–$164.61, $0.28M total) across 2 trades on 2026-08-05.
1 min readCLARK IAN T sold 14,180 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $158.92 ($158.80–$158.98, $2.25M total) across 2 trades on 2026-08-04.
2 min readThe FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.
6 min readBTIG named Guardant Health its top healthcare pick after strong Q2 results. BTIG kept a Buy rating and raised its price target to $195 from $190. Guardant reported Q2 revenue of $335 million, up 44%, and 63% core oncology volume growth, and raised full-year guidance. Catalysts cited include potential CMS coverage for Reveal MRD and launches of Reveal Ultra MRD in 2H 2026 and G360 ADLT status in 1H 2027.
4 min readGuardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.
6 min readGuardant Health shares rose after the company reported Q2 results, according to the article. RBC raised its price target on Guardant Health to $200 from $185 and kept an Outperform rating, the piece said. The stock was quoted at $161.99, up 6.33% on the day.
2 min readAnalyst estimates for Guardant Health, Inc. show its average 12-month price target increased from $177 to $191.09, with a range of $125 to $225 per share, according to FactSet. Based on the Jul. 30 closing price, the target implies about 25% upside. The consensus rating remains “Buy” (25 Buys, 2 Holds, 2 Sells) across 29 analysts.
1 min readGuardant Health shares rose nearly 10% at the open Friday to a new 52-week high after the company reported Q2 2026 revenue above consensus and raised its full-year outlook, according to the article.
2 min readNasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.
4 min read
